Health-Related Quality of Life in a Real-World Cohort of Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.

IF 2.5 3区医学 Q3 ONCOLOGY

Oncology Pub Date : 2025-01-14 DOI:10.1159/000543541

Hiroki Kobayashi, Nobuki Furubayashi, Kaede Morihara, Motonobu Nakamura, Takahito Negishi

{"title":"Health-Related Quality of Life in a Real-World Cohort of Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.","authors":"Hiroki Kobayashi, Nobuki Furubayashi, Kaede Morihara, Motonobu Nakamura, Takahito Negishi","doi":"10.1159/000543541","DOIUrl":null,"url":null,"abstract":"Introduction: Health-related quality of life (HRQOL) has been reported in clinical trials of pembrolizumab and avelumab treatment of locally advanced or metastatic urothelial carcinoma. However, few studies have investigated the effect of immune checkpoint inhibitors (ICIs) on HRQOL in patients with urothelial carcinoma in a real-world setting.Methods: We included 44 patients with advanced urothelial cancer who were treated with pembrolizumab or avelumab from January 2018 to November 2023. When patients visited our hospital for treatment, we evaluated their HRQOL using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 15-Palliative Care. We retrospectively reviewed the interview sheets.Results: The median time to deterioration in global health status was 19.1 weeks. The mean scores of emotional functioning were improved in weeks 18 and 36 compared with baseline. The mean scores for fatigue and appetite loss were also improved in weeks 18 and 36.Conclusion: ICI treatment for advanced urothelial carcinoma did not worsen HRQOL over time in a real-world setting. Tolerability of ICIs for advanced urothelial carcinoma appears good in those who received long-term treatment.","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-9"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000543541","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Health-related quality of life (HRQOL) has been reported in clinical trials of pembrolizumab and avelumab treatment of locally advanced or metastatic urothelial carcinoma. However, few studies have investigated the effect of immune checkpoint inhibitors (ICIs) on HRQOL in patients with urothelial carcinoma in a real-world setting.

Methods: We included 44 patients with advanced urothelial cancer who were treated with pembrolizumab or avelumab from January 2018 to November 2023. When patients visited our hospital for treatment, we evaluated their HRQOL using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 15-Palliative Care. We retrospectively reviewed the interview sheets.

Results: The median time to deterioration in global health status was 19.1 weeks. The mean scores of emotional functioning were improved in weeks 18 and 36 compared with baseline. The mean scores for fatigue and appetite loss were also improved in weeks 18 and 36.

Conclusion: ICI treatment for advanced urothelial carcinoma did not worsen HRQOL over time in a real-world setting. Tolerability of ICIs for advanced urothelial carcinoma appears good in those who received long-term treatment.

查看原文本刊更多论文

免疫检查点抑制剂治疗晚期尿路上皮癌患者的现实世界队列中与健康相关的生活质量

pembrolizumab和avelumab治疗局部晚期或转移性尿路上皮癌的临床试验中已经报道了与健康相关的生活质量（HRQOL）。然而，很少有研究在现实环境中调查免疫检查点抑制剂（ICIs）对尿路上皮癌患者HRQOL的影响。方法：我们纳入了2018年1月至2023年11月期间接受派姆单抗或avelumab治疗的44例晚期尿路上皮癌患者。当患者来我们医院接受治疗时，我们使用欧洲癌症研究和治疗组织生活质量问卷-核心15-姑息治疗评估他们的HRQOL。我们回顾了采访记录。结果：总体健康状况恶化的中位时间为19.1周。与基线相比，情绪功能的平均得分在第18周和第36周有所改善。疲劳和食欲减退的平均得分在第18周和第36周也有所改善。结论：在现实世界中，ICI治疗晚期尿路上皮癌并没有使HRQOL恶化。接受长期治疗的晚期尿路上皮癌患者对ICIs的耐受性良好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.